Lymphocyte activation by recombinant interleukin-2 in ovarian cancer patients.
Peripheral blood lymphocytes from 42 patients and peritoneal cavity lymphocytes from eight patients with advanced ovarian carcinoma were tested for lymphokine-activated killer lymphocyte cytotoxicity against several ovarian carcinoma lines before and after exposure to recombinant interleukin-2 in vitro for 3-5 days. Only four of 42 (9.5%) of peripheral blood lymphocytes and zero of eight (0%) of peritoneal cavity lymphocytes had spontaneous cytotoxicity (greater than 20%) against the ovarian carcinoma lines. After in vitro exposure to recombinant interleukin-2, 41 of 42 (98%) of patients' blood lymphocytes showed a two- to fivefold increase in cytotoxicity against K562 (a lymphoblastoid human target), and 40 of 42 (95%) demonstrated lymphokine-activated killer cytotoxicity (greater than 20%) to the ovarian carcinoma lines. Lymphokine-activated killer activity against fresh allogeneic cell lines was variable, although most patients' peripheral blood lymphocytes (70%) had significant cytotoxicity. By contrast, incubation of patients' peritoneal cavity lymphocytes with recombinant interleukin-2 in vitro did not result in the generation of lymphokine-activated killer cell activity against K562 or ovarian cell lines. Peritoneal lymphocytes did produce lymphokine-activated killer cells in the presence of OK432 in half of the patients tested. The presence of autologous serum during recombinant interleukin-2 activation with blood lymphocytes had an augmentative effect on the resulting lymphokine-activated killer cytotoxicity in two of 20 patients, a suppressive effect in four of 20, and no effect in the other 14 of 20 patients tested.(ABSTRACT TRUNCATED AT 250 WORDS)
Boyer
P J
PJ
Department of Obstetrics and Gynecology, University of California, Los Angeles School of Medicine.
Berek
J S
JS
Zighelboim
J
J
D005260:Female; D006801:Humans; D007376:Interleukin-2 / Q000494:pharmacology*; D007694:Killer Cells, Natural / Q000276:immunology; D008213:Lymphocyte Activation; D010051:Ovarian Neoplasms / Q000276:immunology* / Q000628:therapy; D011994:Recombinant Proteins / Q000494:pharmacology; D014407:Tumor Cells, Cultured
D007376:Interleukin-2; D011994:Recombinant Proteins